Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa

Open Access

Peer-reviewed

Research Article

Richard A. Murphy ,

* E-mail: ramurphy@gmail.com

Affiliation Medical Unit, Médecins Sans Frontières/Doctors Without Borders, New York, New York, United States of America
⨯
Vincent C. Marconi,

Affiliation Infectious Diseases Division, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America
⨯
Rajesh T. Gandhi,

Affiliation Infectious Diseases Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America
⨯
Daniel R. Kuritzkes,

Affiliation Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
⨯
Henry Sunpath

Affiliation Department of Medicine, McCord Hospital and Infectious Diseases Unit, Nelson Mandela School of Medicine, Durban, South Africa
⨯

Reader Comments (0)

Tuberculosis
Is the Subject Area "Tuberculosis" applicable to this article?

Thanks for your feedback.
Protease inhibitor therapy
Is the Subject Area "Protease inhibitor therapy" applicable to this article?

Thanks for your feedback.
Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.
Antiretroviral therapy
Is the Subject Area "Antiretroviral therapy" applicable to this article?

Thanks for your feedback.
Toxicity
Is the Subject Area "Toxicity" applicable to this article?

Thanks for your feedback.
HIV
Is the Subject Area "HIV" applicable to this article?

Thanks for your feedback.
Co-infections
Is the Subject Area "Co-infections" applicable to this article?

Thanks for your feedback.
Viral load
Is the Subject Area "Viral load" applicable to this article?

Thanks for your feedback.